Murine experimental salmonellosis has been one of the most widely accepted models for studying the pathogenesis of and immunity to Salmonella typhi infections in humans. Salmonella typhimurium and Salmonella enteritidis are the causative agents of murine typhoid fever and are generally considered to be facultative intracellular pathogens in this species (4) , although this conclusion has been questioned by some investigators (22) . Current research efforts with this experimental model have focused on the delineation of (i) the precise antigen(s) responsible for the induction of immunity to Salmonella infections and (ii) the immune mechanism(s) which contributes to the elimination of this pathogen from the host following infection. The availability of such information should provide rational experimental approaches for the development of effective antigen vaccines and immunization regimens for S. typhi infections in humans.
Studies with the murine experimental model, however, can be complicated by the natural innate resistance or susceptibility of different inbred strains of mice to Salmonella infections. At the present time, there have been defined at least five genetic loci which contribute to the relative susceptibility or resistance of a particular mouse strain to Salmonella infections. These include (i) the Ity locus, which is located on chromosome 1 (26) ; (ii) the Xid locus, which is sex linked and known to contribute to a general immunodeficiency state in mice (27) ; (iii) an as-yet-undefined locus found in C3HeB/FeJ mice (7, 25) ; (iv) the Lps locus (29) , which is located on chromosome 4 and is also responsible for hyporesponsiveness to the various immunologic and pathologic effects of lipopolysaccharide (LPS) (32) ; and finally (v) a hypothesized single autosomal recessive gene which is believed to regulate late-phase susceptibility to Salmonella infections (28) . Thus, experiments designed to * Corresponding author. evaluate a particular model of murine salmonellosis must be considered within the framework of the relative resistance or susceptibility of the particular mouse strain being used to study immunity to this pathogen.
Many investigators have succeeded in inducing high levels of protective immunity in mice against subsequent lethal doses of Salmonella spp.; however, the nature of the antigen(s) which affords protection has remained controversial. The results of a number of early studies provided data which suggested that only live vaccines capable of inducing cellular immunity had the capacity to protect mice against lethal Salmonella challenge (1, 2, 16). More recent data have not totally confirmed these conclusions. In this respect, a number of vaccines lacking viable Salmonella organisms have been reported by different laboratories to provide significant protection against lethal Salmonella infections (6, 13, 18, 30) . One of the most widely studied Salmonella antigens, which has been implicated for its role in protective immunity, is the LPS component of the outer cell membrane. Of interest, recent studies have suggested that prior immunization with LPS or LPS-protein complexes can be effective in protecting strains of mice that are naturally resistant to Salmonella infections (9) .
The C3H/HeJ strain of mice has been shown to be highly susceptible to Salmonella infections, with as few as two viable bacteria constituting a lethal dose (5) . The genetic basis for this hypersusceptibility has been suggested to be the Lps locus on chromosome 4, which also controls both specific immune responses to LPS and more generalized immunoregulatory responses to LPS. It is, therefore, reasonable to postulate that the lack of appropriate LPSmediated immune responses may contribute to the hypersusceptibility to Salmonella infections observed with this strain. Earlier studies in this laboratory, however, showed that splenocytes, although unresponsive to the im-munostimulatory effects of purified protein-free LPS, respond normally to lipid A-associated protein (LAP), either alone or in a complex with LPS (19) . We have, therefore, designed experiments to determine whether preimmunization with LAP-LPS complexes can provide protection in C3H/HeJ mice subsequently challenged with S. typhimurium LT2. The results of these studies indicate that, in marked contrast to protein-free LPS, LAP-LPS complexes induce highly significant protection against subsequent lethal Salmonella challenge in C3H/HeJ mice. Our data, therefore, support the concept that the inability to induce protective immunity in this strain may be, at least in part, due to the lack of appropriate immunostimulation with LPS.
( Harbor, Maine, and maintained in our animal facilities on a diet of mouse chow and water ad libitum. For most experiments, mice were used for initial immunization or Salmonella challenge between 8 and 12 weeks of age.
Bacterial culture and lethal challenge of C3H/HeJ mice. S. typhimurium LT2 (originally provided by John K. Spitznagel, Emory University School of Medicine, Atlanta, Ga.) was maintained on Trypticase soy agar slants (BBL Microbiology Systems, Cockeysville, Md.) and transferred weekly from single-colony isolates on Trypticase soy agar plates (BBL Microbiology Systems). Microorganisms used for the lethal challenge were inoculated into 50 ml of Trypticase soy broth (BBL Microbiology Systems), and the culture was incubated overnight (approximately 16 h) at 37°C with aeration. Approximately 100 ,ul of the overnight culture was then used to inoculate 50 ml of Trypticase soy broth, and the bacteria were grown to the mid-log phase. The concentration of bacteria was determined by measuring the A650 and comparing the results to a standard curve, and the bacteria were then diluted in sterile saline to the desired concentration just prior to intraperitoneal (i.p.) or intravenous (i.v.) injection into mice. The actual number of bacteria injected was determined by duplicate plating on Trypticase soy agar plates. The mice were subsequently monitored daily over a 60-day period, and the deaths were recorded. All data are expressed as the percentage of mice surviving bacterial challenge.
Isolation of immunogens. S. typhimurium LT2 was grown in 9 liters of Trypticase soy broth for approximately 8 h in a high-density fermentor (New Brunswick Scientific Co., Inc., Edison, N.J.). The temperature and pH were kept constant at 37°C and 7.0, respectively. The bacteria were maintained at 4°C overnight and then harvested by centrifugation at 15,344 x g for 20 min. Following three washes by centrifugation with sterile saline, the bacteria were extracted with cold aqueous butanol and subsequently purified to yield LAP-LPS as described previously (20) . One-half of the LAP-LPS was then subjected to hot phenol water extraction (33) to yield essentially protein-free LPS. The LAP-LPS and protein-free LPS (hereafter referred to as LPS) contained 18% and less than 2.0% protein, respectively, as determined by the Folin phenol procedure (15 (19) . We therefore carried out control experiments to ensure that the Salmonella immunogens prepared for these studies manifested these well-characterized properties. Analysis of LPS and LAP-LPS by SDS-PAGE has provided a highly sensitive assay with which to analyze and compare LPS preparations (31) . When the antigens were stained with silver, the LPS portion of LAP-LPS demonstrated an electrophoretic mobility pattern virtually indistinguishable from that of the purified LPS preparation (Fig. 1A) (Fig. 1B) to detect protein, it was found that protein could only be detected in the LAP-LPS preparation and not in the LPS preparation. Further, the LAP distribution profile in SDS-PAGE for the Salmonella antigen was similar to that which has been observed earlier for the Escherichia coli antigen (21) . Thus, LAP-LPS and LPS manifested the previously described biochemical characteristics.
To characterize these antigens functionally, we assessed the ability of these LPS preparations to stimulate proliferation of cultured splenocytes obtained from C3HeB/FeJ (LPS responsive) or C3H/H3J (LPS hyporesponsive) mice. LPS stimulated proliferation of splenocytes only in C3HeB/FeJ mice, and LAP-LPS stimulated proliferation of splenocytes in both strains of mice (Fig. 2) . Thus, these antigens manifested the previously reported functional properties, as assessed in LPS-responsive and -hyporesponsive mice.
Hypersusceptibility of C3H/HeJ mice to S. typhimurium LT2 infections. C3H/HeJ mice have been reported to be hypersusceptible to various strains of S. typhimurium (5, 7, 24) , with reports of as few as two viable organisms killing all the mice in the infected group. It was therefore important to establish the degree of hypersusceptibility of C3H/HeJ mice to S. typhimurium LT2. To address this question, we injected three groups of 10 C3H/HeJ mice each i.p. with 1,000, 100, or 10 viable S. typhimurium LT2 organisms, monitored the mice daily, and recorded the deaths. As few as 10 viable S. typhimuriuim LT2 organisms were sufficient to kill all the mice in a group (Fig. 3) . It is noteworthy that the mice injected with 1,000 viable S. typhimurium LT2 organisms succumbed more rapidly than the mice injected with 100 or 10 organisms (i.e., at 4 days postinfection there was 30, 70, and 80% survival in the groups infected with 1,000, 100, and 10 S. typhimurium LT2 organisms, respectively). Under these experimental conditions, therefore, in which 10 viable Av I. regimen would maximize the induction of protective immunity to S. typhimurium LT2 if these immunogens proved effective. The data shown in Fig. 4A demonstrate that CFA-saline afforded 0% protective immunity and that 50 pg of CFA-LPS afforded 35% protective immunity to lethal S. typhimurium LT2 infections, as assessed at 60 days postchallenge. Of importance, however, 50 jig of CFA-LAP-LPS afforded almost complete protection, with only one death observed in a group of 17 animals.
To determine whether the CFA component of the immunogens was critical for the survival of C3H/HeJ mice challenged with S. typhimurium LT2, we performed the following experiment. C3H/HeJ mice were immunized i.p. with 50 jig of LAP-LPS, 50 p.g of LPS, or saline, none of which contained CFA. At 28 days postimmunization, the mice were challenged with 100 LD1im of S. typhimurium LT2 (i.e., 1,000 viable bacteria) and monitored daily for survival for 60 days. While saline afforded no survival, immunization with 50 jig of LPS resulted in 40% survival, and immunization with 50 ,ug of LAP-LPS resulted in 100% survival (Fig. 4B) . These results are virtually identical to those obtained when mice were immunized with these immunogens emulsified in CFA (Fig. 4A) . The saline controls, however, were notably different in that maximal survival times were somewhat greater in animals pretreated with CFA. These combined results therefore suggest that although the CFA component of the immunogen does provide some nonspecific effects which prolong the survival of lethal S. typhimurium LT2 infections, the effects are minimal. In addition, however, these combined data indicate that the protein component of LAP-LPS may be important in the induction of significant protection against lethal S. typhimurium LT2 infections in C3H/HeJ mice.
Optimal immunization time and dose of LAP-LPS. The above data demonstrate that LAP-LPS can be effective in protecting C3H/HeJ mice against lethal S. typhimurium LT2 infections. We next wanted to determine the optimal immunization time that was necessary to establish effective protection in these mice. To (Fig. 5) . Minimal protection was obtained when animals were challenged 5 or 15 days postimmunization, i.e., 20 or 30% survival, respectively. Challenge at 22 days postimmunization resulted in 80% protection, and challenge at 29 days postimmunization resulted in complete (100%) survival (Fig. 5) .
To determine the optimal dose of LAP-LPS required to induce immunity to S. typhimurium LT2, we immunized C3H/HeJ mice i.p. with 50, 5, or 0.5 pg of CFA-LAP-LPS and then challenged them with 100 LD1(, of S. typhimurium LT2 (i.e., 1,000 viable bacteria) at 28 days postimmunization. For comparison, C3H/HeJ mice were also immunized with equivalent doses of CFA-LPS. The results ( Fig. 8 , C3H/HeJ mice were not protected (0% survival) by immunization with CFA-LPS when challenged with 1,000 LD1,X, although they were protected (35% survival) from a 120 LD)oo (i.e., 1,200 viable bacteria) challenge (Fig. 4A) . In contrast, C3H/HeJ mice immunized with CFA-LAP-LPS were protected (80% survival) even aganst a 1,000 LDioo challenge, a result very similar to the 94% survival obtained with the 120 LD100 challenge (Fig. 4A) . Long-term immunization of C3H/HeJ mice with LAP-LPS. From a practical standpoint, it was important to determine how long C3H/HeJ mice remain protected against lethal S. typhimuriium LT2 infections after immunization with a dose of CFA-LAP-LPS that induces optimal short-term protection against this pathogen. To address this question, we immunized C3H/HeJ mice i.p. with CFA-saline or 50 ,ug of CFA-LAP-LPS and challenged them with 110 LD100 of S. typhimurium LT2 (i.e., 1,100 viable bacteria) 225 days postimmunization. The mice were monitored for 60 days postchallenge, and the deaths were recorded. Mice immunized with CFA-LAP-LPS (50 ,ug) were protected (67% survival) from lethal S. typhimurilum LT2 challenge (Fig. 9) . Although this extent of survival was slightly lower than that observed at 28 days postimmunization, it can be concluded that immunization with LAP-LPS does result in long-term immunization against lethal S. typhimurium LT2 infections and that this immunity is not a transient event.
DISCUSSION
In this manuscript we have presented data which indicate that Salmonella-hypersusceptible C3H/HeJ mice can be protected to a significant extent and for an extended period of time against lethal challenge with S. typhimurium LT2 by prior immunization with LAP-LPS complexes derived from S. typhimurium LT2. Markedly less protection is afforded to mice immunized with purified LPS. The optimal immunization regimen for inducing protection against S. typhimurium typhimurium LT2 challenge. Protection was diminished to c30% in mice immunized with 50 ,g of CFA-LAP-LPS 15 days or less prior to lethal S. typhimurium LT2 challenge. Markedly less protection was also observed when the immunization dose was 5 ,ug or less of CFA-LAP-LPS 28 days prior to lethal S. typhimurium LT2 challenge (i.e., c40% survival).
LPS and LAP-LPS have been reported to differ biochemically by the absence of protein in the former and the presence of protein in the latter. We confirmed that the antigens used in this study manifested these biochemical characteristics by detection of protein bands with Coomassie blue stain after SDS-PAGE in the LAP-LPS preparation but not in the purified LPS preparation. These antigens, however, do share the same LPS component. We demonstrated this by staining the antigens with silver after they were electrophoresed by SDS-PAGE. The stained antigens revealed virtually the same gel patterns, indicating that the LPS portion of the antigens was not altered by the different solvents used in extracting them. We also estimated, by using the Folin phenol method, that the LAP-LPS preparation contained approximately 18% protein, whereas the LPS preparation contained less than 2% protein. Since the Folin phenol procedure will detect substances other than protein (e.g., phosphorylethanolamine) and since we have been unable to detect protein by SDS-PAGE, it is likely that the protein content of LPS is significantly less than 2%. It is, therefore, probably fair to state that the major difference between the two antigens used in this study is the presence or absence of protein (LAP). These antigens also differ functionally in that LAP-LPS is able to stimulate proliferation of splenocytes isolated from C3H/HeJ mice, whereas the same splenocytes are refractory to stimulation by LPS.
Our data have provided evidence that LAP-LPS complexes provide significant protection against S. typhimurium challenge. In these experiments, we determined the percent survival of the animals infected with S. typhimurium LT2 for 60 (3) . In that study, mice that were immunized i.p. with a nonviable vaccine were afforded 40% protection when challenged i.p. but were afforded 0% protection when challenged i.v. The results presented here, however, contrast with these earlier results and suggest that under some circumstances, mice can be effectively protected against lethal Salmonella challenge regardless of the route of infection.
Protection of C3H/HeJ mice by immunization with nonviable vaccines has, in general, been difficult to demonstrate and, when protection has been obtained, it has been variable and not always reproducible. Whereas in one study by Misfeldt and Johnson, 100% survival of 100 LD50 doses of S. typhimurium was reportedly obtained with a ribosomal vaccine from this organism (18), a second study by these authors with an identical protocol resulted in only 50% survival (17) . Eisenstein et al. have also shown that C3H/HeJ mice can be effectively protected by a live avirulent strain of S. typhimurium, SL3235, which is a smooth aroA-derivative of a virulent parent (8) .
In another study, Eisenstein et al. (9) investigated the potential immunotherapeutic value of LPS-protein complexes in C3H/HeJ mice. They were able to demonstrate a threefold increase in the mean time to death following Salmonella infection in mice immunized with trichloroacetic acid-extracted LPS, and 21% of the mice survived to 60 days. LAP-LPS, used in this study, and trichloroacetic acid-extracted LPS appear to contain similar components, although some minor differences have been noted (10 (11) reported that the protein component of trichloroacetic acid-extracted LPS enhances the secondary immune response to LPS in BALB/c mice. It is also possible that LAP acts as a relevent antigen in a direct cellular or humoral immune response directed against LAP-LPS complexes. In preliminary studies, we have been unable to detect any T-cell response against LAP, although we have detected a humoral immune response directed against LAP. Additional studies are currently in progress to distinguish among these possibilities.
